Guideline Summary: Recognition and Multimodal Monitoring of Vasospasm After Subarachnoid Hemorrhage

Clinical Recognition

The first objective sign of symptomatic vasospasm is the emergence of a new focal neurological deficit (e.g., motor weakness, aphasia, neglect) that cannot be explained by hydrocephalus or re‑bleeding, typically appearing 3–5 days after the initial bleed and peaking between days 5–14. 1
Vasospasm generally begins 3–5 days after SAH, reaches maximal severity between days 5–14, and gradually resolves over 2–4 weeks. 1
Unexplained elevations in mean arterial pressure may occur as cerebral autoregulation attempts to compensate for reduced perfusion. 1
In comatose or poor‑grade patients, a high index of suspicion is required because symptomatic vasospasm can develop without overt clinical change; even subtle examination findings should prompt investigation. [1][2]
Delayed cerebral ischemia (DCI) can progress to infarction without overt neurological deterioration in approximately 50 % of patients who have angiographic vasospasm. 3

Transcranial Doppler (TCD) Monitoring

TCD monitoring is reasonable for detecting vasospasm and predicting DCI (Class IIa, Level B‑NR). 2
Lindegaard ratios (mean cerebral vessel velocity ÷ extracranial ICA velocity) should be used rather than absolute velocities, because absolute values can be misleading during hypertensive therapy. 1
A Lindegaard ratio of 5–6 indicates severe vasospasm that warrants treatment based on the clinical context. 1
Limitations: TCD is operator‑dependent with variable sensitivity and specificity; institutions should implement quality‑control programs and establish site‑specific thresholds. [1][2]

CT Angiography (CTA)

CTA is useful for detecting vasospasm and predicting DCI (Class IIa, Level B‑NR) and provides a sensitivity of ~91 % for central vasospasm when clinical symptoms develop. 2
Compared with conventional angiography, CTA has a diagnostic accuracy of ~90 % and a false‑positive rate of only ~5 %. 2
CTA is especially valuable when TCD velocities are elevated and the neurological examination is limited (e.g., sedated or poor‑grade patients). [2][3]
Accuracy is lower for distal vascular territories (78–81 % for distal vessels versus 96–100 % for proximal vessels). 3

CT Perfusion (CTP)

CTP can detect vasospasm and predict DCI (Class IIa, Level B‑NR) with a pooled sensitivity of 74 % and specificity of 93 % (meta‑analysis). [2][3]
CTP provides information on small‑vessel perfusion, complementing CTA’s assessment of large‑vessel caliber. 3
Guideline note: CTP‑guided therapeutic decisions have not been shown to improve clinical outcomes compared with treating all patients without imaging guidance. 3

Continuous EEG (cEEG) Monitoring

In high‑grade SAH patients, cEEG monitoring is useful for predicting DCI (Class IIa, Level B‑NR). 2
EEG “alarms” (e.g., new epileptiform activity) occur in 96.2 % of patients who subsequently develop DCI, with a median latency of 1.9 days before clinical DCI becomes apparent. 2
Late‑onset epileptiform abnormalities have the highest predictive value among EEG alarm subtypes. 2

Invasive Neuromonitoring

Brain tissue oxygen (PbtO₂), lactate/pyruvate ratio, and glutamate monitoring may be considered in high‑grade SAH (Class IIb, Level B‑NR). 2
Major limitation: these modalities provide only regional information; optimal probe placement in the territory at highest risk for ischemia is essential. 2

Conventional Angiography

Digital subtraction angiography remains the reference standard for definitive vasospasm diagnosis, particularly when endovascular therapy is contemplated. [1][3]
Angiographic vasospasm is observed in 30–70 % of SAH patients, yet only about 50 % of those develop clinical symptoms. [1][3]

Outcomes and Prognosis

Despite maximal therapy, 15–20 % of patients suffer stroke or die from vasospasm, accounting for nearly 50 % of deaths among those who survive to receive treatment. 1
DCI can occur without angiographic vasospasm in ~3 % of patients, whereas severe angiographic vasospasm may be clinically silent in ~50 % of cases. 3

These recommendations reflect the consensus of the American Heart Association/American Stroke Association and the American College of Radiology.

Management of Vasospasm and Hemorrhagic Transformation in Subarachnoid Hemorrhage

Prevention of Cerebral Vasospasm

The American Heart Association recommends administering oral nimodipine 60 mg every 4 hours for 21 consecutive days, starting within 96 hours of initial bleeding, to prevent neurological deficits due to vasospasm (Class I, Level of Evidence A) 4, 5.
Nimodipine reduces cerebral infarct by 34% and adverse outcomes by 40%, although it does not prevent angiographic vasospasm 4, 5.

Diagnosis of Vasospasm

The development of new focal deficit, not explained by hydrocephalus or rebleeding, is the first objective sign of symptomatic vasospasm 6, 7, 8.
Transcranial Doppler (TCD) should be used for monitoring, although its sensitivity and specificity are variable and operator-dependent 6, 7, 8.
Lindegaard indices (ratio of cerebral vessel velocity to extracranial internal carotid artery velocity) of 5-6 indicate severe vasospasm and require treatment based on clinical situation 6, 7, 8.

Treatment of Symptomatic Vasospasm

Induce hypertension while maintaining euvolemia as initial treatment when delayed cerebral ischemia is diagnosed 5, 9, 10.
Angioplasty with balloon is effective for reversing cerebral vasospasm in large proximal conducting vessels with thick muscular walls 11, 4.
Vasodilators, such as papaverine, can be used to treat third- and fourth-order vessels that cannot be treated with balloon angioplasty 11.

Management of Systemic Complications

Aggressively control fever towards normothermia using standard or advanced temperature modulation systems in the acute phase of subarachnoid hemorrhage (Class IIa, Level of Evidence B) 12, 13.
Use fludrocortisone acetate and hypertonic saline to prevent and correct hyponatremia (Class IIa, Level of Evidence B) 13.

Prognosis

Angiographic vasospasm occurs in 30-70% of patients, with typical onset 3-5 days after hemorrhage, maximum narrowing at 5-14 days, and gradual resolution over 2-4 weeks 6, 8.
Approximately half of cases manifest with delayed cerebral ischemic neurological deficit, which with equal probability may resolve or progress to cerebral infarct 6, 8.
In contemporary series, 15-20% of patients suffer stroke or die from vasospasm despite maximal therapy 6, 7, 8.

Evidence‑Based Facts on Delayed Cerebral Ischemia (DCI) after Aneurysmal Subarachnoid Hemorrhage

Predictors of DCI

In patients with aneurysmal SAH, the amount, anatomical location, density of subarachnoid blood, and speed of clot clearance are the strongest predictors of subsequent DCI. [Stroke 2020] 14
A higher Fisher grade on initial CT correlates with a greater risk of developing vasospasm, a major contributor to DCI. [Journal of the American College of Radiology 2021] 15

Role of Perfusion Imaging in Treatment Decisions

CT perfusion‑guided therapy does not improve clinical outcomes compared with a strategy of treating all patients without imaging guidance. [Journal of the American College of Radiology 2021] 16

Clinical Manifestations of Angiographic Vasospasm

Among patients who exhibit severe large‑vessel vasospasm, only ≈50 % develop overt ischemic symptoms, and DCI can still occur in the absence of angiographic vasospasm. [Journal of the American College of Radiology 2021] 16

Endovascular Therapy for Refractory Vasospasm

Endovascular interventions (e.g., balloon angioplasty, intra‑arterial vasodilators) can reverse angiographic vasospasm, but high‑quality evidence that these procedures improve neurological outcomes is lacking. [Journal of the American College of Radiology 2021] [17][18]

Implications of Randomized Trials on Vasospasm Reduction

Randomized controlled trials that achieved reduction of angiographic vasospasm did not translate into better overall patient outcomes, underscoring that DCI involves mechanisms beyond simple arterial narrowing (e.g., microvascular dysfunction, inflammation). [Stroke 2020] 14